Advisory Board July 31, 2024

As demand for GLP-1 drugs like Ozempic and Wegovy continues to rise, some patients are turning to compounded versions of the drugs, which face fewer safety regulations. Now, there have been a growing number of reports of patients accidentally overdosing on these compounded drugs, leading to severe side effects.

5 catalysts that will impact the future of weight management drugs

Background

Semaglutide is a GLP-1 drug manufactured by Novo Nordisk. In 2017, FDA approved the drug to treat type 2 diabetes under the brand name Ozempic. A higher dose of the drug was later approved to treat obesity under the brand name Wegovy in 2021.

As demand increased, patients faced more difficulty accessing the drug, in part due to ongoing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Patient / Consumer, Pharma / Biotech, Provider
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article